ENSC Ensysce Biosciences, Inc. Stock Quote

ENSC [NASD]

Index	-	P/E	0.90	EPS (ttm)	0.45	Insider Own	33.90%	Shs Outstand	6.22M	Perf Week	-0.69%
Market Cap	9.90M	Forward P/E	-	EPS next Y	-	Insider Trans	1.18%	Shs Float	-	Perf Month	-12.19%
Income	2.90M	PEG	-	EPS next Q	-	Inst Own	14.50%	Short Float	-	Perf Quarter	-28.78%
Sales	-	P/S	-	EPS this Y	978.50%	Inst Trans	-	Short Ratio	0.57	Perf Half Y	-59.30%
Book/sh	0.30	P/B	1.34	EPS next Y	-	ROA	22.50%	Target Price	-	Perf Year	-89.35%
Cash/sh	0.00	P/C	-	EPS next 5Y	-	ROE	107.10%	52W Range	0.39 - 7.00	Perf YTD	-91.43%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-94.93%	Beta	-0.11
Dividend %	-	Quick Ratio	0.70	Sales past 5Y	-	Gross Margin	-	52W Low	-9.74%	ATR	0.05
Employees	-	Current Ratio	0.70	Sales Q/Q	-70.90%	Oper. Margin	-	RSI (14)	34.68	Volatility	7.48% 13.47%
Optionable	No	Debt/Eq	0.26	EPS Q/Q	-197.80%	Profit Margin	-	Rel Volume	2.29	Prev Close	0.40
Shortable	Yes	LT Debt/Eq	0.26	Earnings	-	Payout	0.00%	Avg Volume	1.27M	Price	0.35
Recom	-	SMA20	-20.30%	SMA50	-31.79%	SMA200	-74.08%	Volume	610,228	Change	-11.85%

Sep-06-22 04:15PM	Ensysce Biosciences Reminds Shareholders to Vote at Upcoming Special Meeting ACCESSWIRE
Sep-01-22 11:14AM	Ensysce Biosciences, Quotient Partner To Work On Novel Opioid To Prevent Abuse and Overdose Benzinga
Aug-31-22 12:54PM	Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose PR Newswire
08:05AM	Ensysce Biosciences Debuts Redesigned Company Website to Highlight its TAAP(TM) and MPAR(TM) Technologies and Growing Product Pipeline ACCESSWIRE
Aug-24-22 08:05AM	Ensysce Biosciences, Inc. Announces Participation in Upcoming Conferences ACCESSWIRE +8.80%
Aug-23-22 08:05AM	Ensysce Biosciences Announces Completion of Clinical Portion of Human Abuse Potential Trial PF614-103 ACCESSWIRE
Aug-17-22 09:20AM	ENSC: Continues to Fight a Plague on Society Zacks Small Cap Research +13.36%
08:01AM	Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call ACCESSWIRE
Aug-11-22 04:10PM	Ensysce Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results ACCESSWIRE -5.90%
Aug-09-22 04:20PM	Ensysce Biosciences Announces Completion of $8 Million Convertible Note Financing ACCESSWIRE +16.31%
Jul-27-22 08:05AM	Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call ACCESSWIRE -8.40%
Jul-13-22 04:05PM	Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study ACCESSWIRE
Jul-01-22 08:30AM	Ensysce Biosciences Secures $8 Million Convertible Note Financing ACCESSWIRE -34.48%
Jun-27-22 09:15AM	Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform ACCESSWIRE +8.22%
Jun-21-22 08:00AM	Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting ACCESSWIRE -7.30%
May-23-22 04:10PM	Ensysce Biosciences Announces Initiation of First Human Abuse Potential Study ACCESSWIRE
May-17-22 08:35AM	ENSC: Test Results Encouraging in Opioid Fight Zacks Small Cap Research -7.09%
May-12-22 04:10PM	Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results ACCESSWIRE
May-05-22 05:15PM	Ensysce Biosciences Releases 2021 Annual Shareholder Letter ACCESSWIRE -6.52%
09:15AM	Ensysce Biosciences Announces New Clinical Results from Trials PF614-102 and PF614-MPAR-101 ACCESSWIRE
Apr-20-22 04:05PM	Dr. Lynn Kirkpatrick, Invited Speaker at SMi 22nd Annual Pain Therapeutics Conference in London UK ACCESSWIRE
Apr-18-22 04:05PM	Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer ACCESSWIRE
Apr-06-22 09:15AM	ENSC: Ensysce Releases Encouraging Financials Zacks Small Cap Research +8.27%
Mar-31-22 04:05PM	Ensysce Biosciences Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire +5.56%
Mar-24-22 05:10PM	Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call ACCESSWIRE
Mar-01-22 05:05AM	ENSC: Ensysce Continues to Progress in Fight Against Opioids Zacks Small Cap Research +12.50%
Feb-23-22 08:31AM	Ensysce Biosciences Announces Participation in the 34th Annual Roth Conference GlobeNewswire
Feb-08-22 04:01PM	Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors GlobeNewswire
Jan-31-22 04:01PM	Ensysce Biosciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program GlobeNewswire
Jan-27-22 08:30AM	Ensysce Biosciences Announces Results of Special Meeting of Stockholders GlobeNewswire -9.34%
Jan-19-22 04:19PM	Ensysce Biosciences Reminds Stockholders to Vote at Upcoming Special Meeting GlobeNewswire -10.40%
Jan-10-22 08:00AM	Ensysce Biosciences Announces First Cohort Dosing in Bioequivalence (BE) Study of Novel TAAP Opioid GlobeNewswire -7.77%
Jan-05-22 04:05PM	Ensysce Biosciences Announces Participation in the H.C. Wainwright BIOCONNECT Conference GlobeNewswire
Jan-04-22 08:00AM	Ensysce Biosciences Achieves Successful Completion of Part A of Multiple-Ascending Dose (MAD)/Bioequivalents (BE) Trial for its Next Generation Opioid, PF614 GlobeNewswire
Jan-03-22 02:44PM	Short Squeeze Stocks: ISIG, AVCT and 5 Others Experts Think Are Ready to Pop InvestorPlace -8.72%
Dec-24-21 06:31AM	Ensysce Biosciences (NASDAQ:ENSC) shareholders are up 57% this past week, but still in the red over the last year Simply Wall St.
Dec-15-21 04:05PM	Ensysce Biosciences Announces First Patients Enrolled in Phase 1 Study of PF614-MPAR, its unique technology platform to provide opioid overdose protection GlobeNewswire +17.43%
Dec-09-21 10:29AM	ENSC Stock Alert: What Investors Are Saying About Ensysce Biosciences as Shares Soar Today InvestorPlace +66.78%
08:34AM	ENSC: Tackling the Opioid Crisis Zacks Small Cap Research
07:33AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday InvestorPlace
Nov-30-21 08:00AM	Ensysce Biosciences Announces Clinical Trial Progress of its New Class of Opioids GlobeNewswire
Nov-15-21 05:32PM	Ensysce Biosciences Reports Third Quarter 2021 Financial Results and Recent Corporate Updates GlobeNewswire
Nov-08-21 08:00AM	Ensysce Biosciences Announces Completion of $15 Million Convertible Note Financing GlobeNewswire
Oct-26-21 08:00AM	Ensysce Biosciences Grows its Management Team with Appointment of Dr. Linda Pestano as Chief Development Officer GlobeNewswire +8.72%
Sep-27-21 08:00AM	Ensysce Biosciences Announces $15 Million Convertible Note Financing GlobeNewswire -11.80%
Sep-08-21 08:00AM	Ensysce Biosciences Announces Treatment of First Cohort for Subjects in Clinical Study of its Next Generation Opioid, PF614 GlobeNewswire
Aug-31-21 08:00AM	Ensysce Biosciences Sets September 2021 Conference Schedule ACCESSWIRE
Aug-19-21 08:00AM	Ensysce Biosciences to Host Satellite Symposium with Dr. Jeffrey Gudin at PAINWeek 2021 on September 9, 2021 GlobeNewswire +22.36%
Aug-16-21 04:45PM	Ensysce Biosciences Reports Second Quarter 2021 Financial Results and Recent Corporate Updates GlobeNewswire -11.59%
Aug-05-21 08:00AM	Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof GlobeNewswire +11.25%
Jul-26-21 08:00AM	Ensysce Biosciences Bolsters Management Team with Appointments of David J. Kovacs as VP Public Policy and David Tanzer as VP Strategic Development GlobeNewswire -10.25%
Jul-21-21 08:00AM	Ensysce Biosciences to Host Virtual Investor Day on July 27, 2021 GlobeNewswire -11.47%
Jul-08-21 08:00AM	Ensysce Biosciences Receives Notice of Award for Year Three of Multi-Year NIDA Grant for the Clinical Development of its Next Generation Opioid Products with Overdose Protection GlobeNewswire

Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is based in La Jolla, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kirkpatrick Lynn	Chief Executive Officer	May 26	Buy	0.53	27,000	14,216	381,851	May 27 02:05 PM
Kirkpatrick Lynn	Chief Executive Officer	May 25	Buy	0.49	70,000	34,083	354,851	May 27 02:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience